Eli Lilly Option Alert: Jun, 2027 $600 Puts at the Bid: 100 vs 125 OI; Earnings 8/7 Before Open 

Eli Lilly Option Alert: Jun, 2027 $600 Puts at the Bid: 100 @ $55.5 vs 125 OI; Earnings 8/7 Before Open Ref=$764.29

Eli Lilly Option Alert: Mar 20 $500 Calls Sweep (15) near the Ask: 200 vs 332 OI; Earnings 8/7 Before Open 

Eli Lilly Option Alert: Mar 20 $500 Calls Sweep (15) near the Ask: 200 @ $293.85 vs 332 OI; Earnings 8/7 Before Open Ref=$767.265

Eli Lilly Option Alert: Mar 20 $500 Calls Sweep (12) near the Ask: 22 vs 4 OI; Earnings 8/7 Before Open 

Eli Lilly Option Alert: Mar 20 $500 Calls Sweep (12) near the Ask: 22 @ $293.85 vs 4 OI; Earnings 8/7 Before Open Ref=$772.72

Eli Lilly Option Alert: Mar 20 $500 Calls Sweep (29) near the Ask: 37 vs 4 OI; Earnings 8/7 Before Open 

Eli Lilly Option Alert: Mar 20 $500 Calls Sweep (29) near the Ask: 37 @ $293.933 vs 4 OI; Earnings 8/7 Before Open Ref=$772.495

Eli Lilly Option Alert: Mar 20 $500 Calls Sweep (12) near the Bid: 26 vs 4 OI; Earnings 8/7 Before Open 

Eli Lilly Option Alert: Mar 20 $500 Calls Sweep (12) near the Bid: 26 @ $293.0 vs 4 OI; Earnings 8/7 Before Open Ref=$772.105

Eli Lilly Option Alert: Mar 20 $500 Calls Sweep (13) near the Bid: 30 vs 4 OI; Earnings 8/7 Before Open 

Eli Lilly Option Alert: Mar 20 $500 Calls Sweep (13) near the Bid: 30 @ $292.95 vs 4 OI; Earnings 8/7 Before Open Ref=$772.025

Eli Lilly Option Alert: Mar 20 $500 Calls Sweep (12) near the midpoint: 22 vs 4 OI; Earnings 8/7 Before Open 

Eli Lilly Option Alert: Mar 20 $500 Calls Sweep (12) near the midpoint: 22 @ $292.85 vs 4 OI; Earnings 8/7 Before Open Ref=$772.025

Eli Lilly Option Alert: Mar 20 $500 Calls Sweep (4) near the Bid: 100 vs 4 OI; Earnings 8/7 Before Open 

Eli Lilly Option Alert: Mar 20 $500 Calls Sweep (4) near the Bid: 100 @ $288.0 vs 4 OI; Earnings 8/7 Before Open Ref=$762.63

Eli Lilly Option Alert: Mar 20 $400 Calls at the Bid: 93 vs 3 OI; Earnings 8/7 Before Open 

Eli Lilly Option Alert: Mar 20 $400 Calls at the Bid: 93 @ $378.05 vs 3 OI; Earnings 8/7 Before Open Ref=$761.075

Eli Lilly Option Alert: Sep 19 $600 Calls Sweep (3) near the Bid: 100 vs 57 OI; Earnings 8/7 Before Open 

Eli Lilly Option Alert: Sep 19 $600 Calls Sweep (3) near the Bid: 100 @ $172.0 vs 57 OI; Earnings 8/7 Before Open Ref=$760.83

Eli Lilly Option Alert: Jun, 2026 $620 Puts at the Bid: 200 vs 461 OI; Earnings 8/7 Before Open 

Eli Lilly Option Alert: Jun, 2026 $620 Puts at the Bid: 200 @ $35.0 vs 461 OI; Earnings 8/7 Before Open Ref=$782.623

Eli Lilly Option Alert: Aug 1 $780 Calls at the Ask: 356 vs 801 OI; Earnings 8/7 Before Open 

Eli Lilly Option Alert: Aug 1 $780 Calls at the Ask: 356 @ $25.4 vs 801 OI; Earnings 8/7 Before Open Ref=$781.5

Eli Lilly Option Alert: Aug 1 $780 Calls at the Ask: 270 vs 283 OI; Earnings 8/7 Before Open 

Eli Lilly Option Alert: Aug 1 $780 Calls at the Ask: 270 @ $21.9 vs 283 OI; Earnings 8/7 Before Open Ref=$773.51

Eli Lilly (NYSE:LLY) Bolsa

Eli Lilly

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Eli Lilly and Co

Novo Nordisk

Equities

FTXH

iShares Dow Jones US Pharmaceuticals Index Fund

KURE

PILL

Merrill Lynch Pharmaceutical HOLDRs Trust

RHHBY

Los aranceles de Trump podrían afectar a Novo Nordisk y otros gigantes farmacéuticos. Barclays advierte de impacto en márgenes y suministro.

Novo Nordisk, en la mira por los posibles aranceles farmacéuticos de Trump

Siegen,,North,Rhine,Westphalia,,,Germany,-,10,11,2023:

Biotech

Large Cap

News

Eurozone

Health Care

General

Novo Nordisk busca la aprobación de la EMA para una dosis de 7,2 mg de Wegovy tras mostrar una pérdida de peso del 21 % en ensayos clínicos.

Novo Nordisk solicita aprobación en Europa para nueva dosis de Wegovy contra la obesidad

España investiga a Novo Nordisk por publicidad encubierta, mientras Reino Unido estudia factores genéticos en riesgos de medicamentos GLP-1.

Novo Nordisk bajo investigación:riesgos genéticos y posible publicidad encubierta en España

Liberty Media Corporation - Series A Liberty Live Common Stock

Liberty Live Group

LIBERTY LIVE SERIES B by Liberty Media Corporation

Liberty Media Corporation - Series C Liberty Live Common Stock

Tidal Trust II Defiance Daily Target 2X Long LLY ETF

The Bristol Myers Squibb Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) and Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) alliance announced a new direct-to-patient option for purchasing Eliquis (apixaban) via the alliance&#8217;s patient resource, Eliquis 360 <a href="https://www.benzinga.com/general/health-care">Support, on Thursday.</a>
Eliquis is a blood-thinning medication that reduces blood clotting and prevents strokes.
In May 2024, Pfizer said it is&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/38595739/pfizer-prospects-garner-mixed-sentiment-from-analysts-finally-the-pivot-investors-h" rel="noreferrer noopener">looking to build</a> on the success of its&nbsp;COVID-19&nbsp;vaccine rollout by introducing a direct-to-consumer medicines platform under the brand "Pfizer for All."&nbsp;
In August 2024, Pfizer introduced&nbsp;the PfizerForAll&nbsp;<a target="_blank" href="https://www.benzinga.com/insights/options/25/03/44202700/pfizers-options-a-look-at-what-the-big-money-is-thinking" rel="noreferrer noopener">digital platform in collaboration</a> with UpScriptHealth, Alto Pharmacy, and Instacart.
The move, as reflected in a recent trademark application, aims to provide medical information, mail-order pharmacy services, and telehealth <a href="https://www.benzinga.com/top-stories/24/05/38798101/pfizer-follows-eli-lillys-footsteps-to-sell-medicines-directly-to-patients" target="_blank" rel="noreferrer noopener">services to US patients</a>.
The offering provides an opportunity for uninsured, underinsured, or self-pay patients to lower their <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/b46462973/bristol-myers-squibb-and-pfizer-announce-direct-to-patient-eliquis-apixaban-option" rel="noreferrer noopener">out-of-pocket costs</a>.
Beginning Sept. 8, eligible U.S. patients with an Eliquis prescription may purchase the medicine directly through Eliquis 360 Support. They will pay a discounted rate of more than 40% less than the current list price.
The program will provide direct shipping to patients across all 50 states and Puerto Rico, offering an additional, simplified option for accessing Eliquis and full transparency into the associated costs.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46400278/is-bristol-myers-squibb-still-an-undervalued-biopharma-play" rel="noreferrer noopener">Is Bristol-Myers Squibb Still An Undervalued Biopharma Play?</a>
With more than 15 million Americans having been prescribed Eliquis since its launch, the medicine has resulted in an estimated $3 billion in total healthcare cost savings and avoidance, including hospitalization and extended rehabilitation needs, for every 100,000 patients treated.
The Wall Street Journal was the first to <a target="_blank" href="http://www.wsj.com/health/pharma/bristol-myers-and-pfizer-to-offer-blockbuster-blood-thinner-at-discount-3c0513ef" rel="noreferrer noopener">report</a> the update.
The report, citing a source, stated that the Bristol-Pfizer partnership opted to launch direct sales of Eliquis following discussions with the Trump administration about making the drug more affordable.
Eliquis, which normally costs $606 for a 30-day supply, will now be sold directly to patients for a reduced cash price of $346 per month.
In the past, drugmakers didn't sell their medicines straight to consumers. Instead, they used middlemen called wholesalers to distribute the drugs and depended on insurance companies to cover most of the costs.
In January 2024, drugmaker Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) became the first to launch a new website allowing patients to get a prescription for weight loss <a href="https://www.benzinga.com/general/biotech/24/01/36495250/eli-lilly-launches-website-to-help-patients-with-home-delivery-options-for-weight-loss-medicines" target="_blank" rel="noreferrer noopener">through a telehealth provider</a>.
LillyDirect&nbsp;offers disease management resources, including access to independent healthcare providers, tailored support, and direct home delivery of select Lilly medicines through third-party pharmacy dispensing services.
In March 2025, in a letter addressed to UpScriptHealth CEO Peter Ax, senators expressed concern about the financial relationship between Pfizer and UpScriptHealth, given its potential implications for the federal <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44311862/pfizers-direct-to-consumer-model-faces-scrutiny-from-us-senators" rel="noreferrer noopener">Anti-Kickback Statute (AKS)</a>.
The letter states that the PfizerForAll program, funded by the drugmaker, appears to be designed to direct patients toward specific drugs, which could lead to unnecessary prescriptions and higher costs for federal healthcare programs.
The letter notes that pharmaceutical companies, including Pfizer, spend approximately $6 billion annually on Direct-to-consumer (DTC) advertising.
Price Action: PFE stock is down 0.08% at $24.59, and BMY stock is up 1.51% at $47.88 at the last check on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/technicals/25/07/46476087/netflix-bulls-are-winning-the-binge-but-is-a-plot-twist-coming-after-earnings" target="_blank" rel="noreferrer noopener">Netflix Bulls Are Winning The Binge — But Is A Plot Twist Coming After Earnings?</a></li>
</ul>
Photo: Shutterstock

Bristol‑Myers Squibb, Pfizer Set To Launch Direct‑To‑Patient Eliquis At 40% Off

GLP-1 medications are delivering a $6.5 billion blow to U.S. grocery spending, with weight-loss drugs fundamentally altering consumer food purchasing patterns across America&#8217;s retail landscape.
What Happened: Big Chalk Analytics reports that users of glucagon-like peptide-1 receptor agonists, including Novo Nordisk A/S&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Ozempic and Wegovy alongside Eli Lilly and Co.&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Mounjaro and Zepbound, have significantly reduced their grocery expenditures. 
The firm&#8217;s survey of 4,500 consumers reveals an additional 8.3% of Americans plan to start these medications, potentially triggering $4.4 billion to $10.8 billion in further grocery losses.
Currently, 11.2% of U.S. adults use GLP-1 medications, with penetration potentially reaching 20% within twelve months. The drugs have generated grocery volume losses between 1.2% and 2.9%, while dollar sales dropped 0.9% to 2.3% across categories, according to Big Chalk&#8217;s analysis.
&#8220;GLP-1s have crossed the household-penetration threshold where their impact on grocery volumes and dollar sales can no longer be ignored,&#8221; said Rick Miller, partner at Big Chalk Analytics. &#8220;This is measurable, structural change.&#8221;
See Also:&nbsp;<a href="https://www.benzinga.com/markets/tech/25/07/46460070/elon-musks-xai-faces-industry-backlash-over-reckless-ai-safety-practices-as-regulatory-scrutiny-intensifies" target="_blank" rel="noreferrer noopener">Elon Musk's xAI Faces Industry Backlash Over ‘Reckless' AI Safety Practices As Regulatory Scrutiny Intensifies</a>
Why It Matters: The appetite-suppressing effects have reshaped purchasing behavior across key categories. GLP-1 users demonstrate 65% higher likelihood of buying smaller cereal packages, 48% preference for reduced lunch meat portions, and 36% inclination toward smaller soft drink sizes.
&#8220;If grocery stores are seeing volume drops, we should expect lower prices under normal supply-demand dynamics,&#8221; Kevin Thompson, CEO of 9i Capital Group, <a href="https://www.newsweek.com/ozempic-costing-grocery-stores-billions-2099920">told</a> Newsweek. &#8220;That&#8217;s not materializing yet.&#8221;
The pharmaceutical sector faces additional headwinds as the Trump administration considers up to 200% tariffs on drug companies. Barclays <a href="https://www.benzinga.com/markets/equities/25/07/46435899/trumps-pharma-tariffs-can-hit-novo-nordisk-says-barclays-expert-but-its-difficult-to-predict-as-drugmakers-have-complex-supply-chains">warns such levies</a> would &#8220;inflate production costs, compress profit margins, and risk supply chain disruptions,&#8221; particularly impacting Novo Nordisk given its Danish manufacturing base for Wegovy&#8217;s active ingredients.
Long-term adherence data reveal sustainability challenges, with only 8.1% of patients maintaining GLP-1 obesity therapy after three years, though one-year Wegovy persistence <a href="https://www.benzinga.com/news/health-care/25/07/46269816/wegovy-zepbound-prices-drop-but-most-patients-still-cant-afford-long-term-use-coverage-is-not-the-same-as-access-says-expert">improved from 33.2% in 2021 to 62.7% in 2024</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/07/46458652/tim-cooks-new-job-is-keeping-trump-happy-says-economist-justin-wolfers-innovation-takes-a-back-seat-to-political-favoritism" target="_blank" rel="noreferrer noopener">Tim Cook&#8217;s New Job Is Keeping Trump ‘Happy,&#8217; Says Economist Justin Wolfers: ‘Innovation Takes A Back Seat To Political Favoritism&#8217;</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo by KK Stock via Shutterstock

Markets

Ozempic, Mounjaro Users Cut $6.5 Billion From Grocery Bills: GLP-1 Boom Triggers Panic In Packaged Food Aisles

WIIM

ABBV

Shares of pharmaceutical stocks are trading higher after JNJ increased its guidance.

Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) has outperformed the market over the past 10 years by 13.38% on an annualized basis producing an average annual return of 24.76%. Currently, Eli Lilly has a market capitalization of $702.36 billion. 
Buying $1000 In LLY: If an investor had bought $1000 of LLY stock 10 years ago, it would be worth $8,899.40 today based on a price of $781.99 for LLY at the time of writing.
<h3>Eli Lilly's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752676211_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

As the Donald Trump administration plans up to 200% tariffs on pharmaceutical companies, Emily Field, head of European pharma research at Barclays, has said that it&#8217;s hard to predict which firm would be affected the most by these tariffs, except for Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>).
Check out the current price of&nbsp;<a href="https://www.benzinga.com/quote/NVO">NVO stock here</a>.
What Happened: Explaining that the pharmaceutical companies as a whole are &#8220;out of favor&#8221; for tariffs, Field <a href="https://www.cnbc.com/video/2025/07/14/barclays-the-pharma-sector-is-very-out-of-favor-for-tariffs.html">told</a> CNBC that it was hard to single out a company that could be the most affected by the levies.
&#8220;It&#8217;s really difficult to say because they have really complex supply chains and companies like to keep it under the wraps,&#8221; she said, adding that &#8220;Novo Nordisk has been called out just because we know a lot of active pharmaceutical ingredients for Wegovy are manufactured in Denmark, so that&#8217;s just one that investors have highlighted.&#8221;
She adds, &#8220;But that could also just be because we have a more concrete idea of how their drug flows. But for the most part, this sector is just very out of favor for tariffs.&#8221;
Talking about the European pharma companies that were planning to invest in the U.S., Field mentioned Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>), Roche Holdings AG (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTCQX">RHHBY</a>), and AstraZeneca PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>).
&#8220;We have seen from a number of European companies very significant announcements about manufacturing investments in the United States. We have seen that from Novartis, Roche, and we also know that the companies are working with the administration on this &#8216;Most Favored Nation&#8217; (MFN) drug pricing policy,&#8221; she said.
She also added that AstraZeneca is likely considering changing its registration to the U.S. &#8220;All of the companies based in Europe are emphasizing that they are very committed to the U.S. and manufacturing in the U.S.&#8221;
According to Field, this is all connected in some way. &#8220;It could be a combination of tariffs and drug pricing that the industry and administration can strike a deal that is favorable to both parties,&#8221; Field explained.
See Also: <a href="https://www.benzinga.com/markets/tech/25/07/46400448/dan-ives-bets-on-cybersecurity-as-biggest-subsector-in-tech-for-2025-expects-strong-q2-earnings-from-crowdstrike-zscaler-palo-alto-check-point">Dan Ives Bets On Cybersecurity As &#8216;Biggest Subsector&#8217; In Tech For 2025; Expects Strong Q2 Earnings From CrowdStrike, Zscaler, Palo Alto, Check Point</a>
Why It Matters: Barclays has also <a href="https://www.benzinga.com/markets/equities/25/07/46364024/trump-threatens-200-pharma-tariffs-but-analyst-says-this-stock-is-immune-and-expected-to-benefit-from-levies">cautioned that a 200% pharma tariff</a> would &#8220;inflate production costs, compress profit margins, and risk supply chain disruptions." 
&#8220;We are waiting for the results of the Section 232 investigation from the Commerce Ministry, which is supposed to come by the end of the month. Prior to Trump saying that he was going to announce 200%, I think most have been expecting 25%; however, the industry&#8217;s response is that tariffs will be negative for patients, as it could result in drug shortages,&#8221; Feild said.
These are some pharma ETFs that could be impacted as the long-awaited industry-wide tariffs would be announced &#8220;very soon,&#8221; according to Trump.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Pharma ETFs</td>
<td>YTD Performance</td>
<td>One-Year Performance</td>
</tr>
<tr>
<td>VanEck Pharmaceutical ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPH#NASDAQ">PPH</a>)</td>
<td>0.45%</td>
<td>-6.90%</td>
</tr>
<tr>
<td>iShares US Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>)</td>
<td>1.01%</td>
<td>-3.91%</td>
</tr>
<tr>
<td>Invesco Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PJP#NYSE">PJP</a>)</td>
<td>-1.22%</td>
<td>-3.19%</td>
</tr>
<tr>
<td>SPDR S&amp;P Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPH#NYSE">XPH</a>)</td>
<td>-1.95%</td>
<td>-1.55%</td>
</tr>
<tr>
<td>KraneShares MSCI All China Health Care Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KURE#NYSE">KURE</a>)</td>
<td>29.34%</td>
<td>33.78%</td>
</tr>
<tr>
<td>First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTXH#NASDAQ">FTXH</a>)</td>
<td>-3.88%</td>
<td>-8.36%</td>
</tr>
<tr>
<td>Direxion Daily Pharmaceutical &amp; Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PILL#NYSE">PILL</a>)</td>
<td>-18.59%</td>
<td>-24.16%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, ended mixed on Tuesday. The SPY was down 0.43% at $622.14, while the QQQ advanced 0.092% to $556.72, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pr</a>o data.
On Wednesday, the futures of the S&amp;P 500, Dow Jones, and Nasdaq 100 indices were trading lower.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/hedge-funds/25/07/46386374/stanley-druckenmillers-duquesne-dumps-palantir-bets-big-on-this-dividend-play-which-has-surged-nearly-50-in-2025">Stanley Druckenmiller&#8217;s Duquesne Dumps Palantir, Bets Big On This Dividend Play Which Has Surged Nearly 50% In 2025</a></li>
</ul>
Photo courtesy: JHVEPhoto / Shutterstock.com

Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains'

<a href="https://www.barrons.com/articles/chinese-biotech-obesity-zepbound-lilly-trial-38914a27" title="https://www.barrons.com/articles/chinese-biotech-obesity-zepbound-lilly-trial-38914a27">https://www.barrons.com/articles/chinese-biotech-obesity-zepbound-lilly-trial-38914a27</a>

Global

Reported Earlier: "Lilly's Zepbound Faces a Potential Weight-Loss Rival. It's Made by a Chinese Biotech." - Barron's

Eli Lilly's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) short percent of float has fallen 3.96% since its last report. The company recently reported that it has 7.71 million shares sold short, which is 0.97% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.24 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Eli Lilly Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752602438_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Eli Lilly has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Eli Lilly's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Eli Lilly's peer group average for short interest as a percentage of float is 3.45%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Do Investors Really Feel About Eli Lilly?

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$270.00</td>
<td>$663.7K</td>
<td>1.8K</td>
<td>3.3K</td>
</tr>
<tr>
<td>EW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$72.50</td>
<td>$44.4K</td>
<td>6.5K</td>
<td>2.2K</td>
</tr>
<tr>
<td>JANX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$22.50</td>
<td>$89.6K</td>
<td>288</td>
<td>427</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/25/25</td>
<td>$800.00</td>
<td>$45.5K</td>
<td>194</td>
<td>213</td>
</tr>
<tr>
<td>TEVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$12.00</td>
<td>$56.2K</td>
<td>5.4K</td>
<td>130</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$70.00</td>
<td>$128.7K</td>
<td>1.3K</td>
<td>91</td>
</tr>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>08/29/25</td>
<td>$59.00</td>
<td>$28.0K</td>
<td>2</td>
<td>56</td>
</tr>
<tr>
<td>BBIO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>08/15/25</td>
<td>$40.00</td>
<td>$28.1K</td>
<td>1.6K</td>
<td>42</td>
</tr>
<tr>
<td>TMO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$340.00</td>
<td>$59.2K</td>
<td>170</td>
<td>31</td>
</tr>
<tr>
<td>HCA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$360.00</td>
<td>$25.0K</td>
<td>159</td>
<td>23</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we notice a put option sweep that happens to be bullish, expiring in 185 day(s) on January 16, 2026. This event was a transfer of 299 contract(s) at a $270.00 strike. This particular put needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $663.7K, with a price of $2220.0 per contract. There were 1803 open contracts at this strike prior to today, and today 3308 contract(s) were bought and sold. 
• Regarding EW (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>), we observe a call option trade with bullish sentiment. It expires in 31 day(s) on August 15, 2025. Parties traded 67 contract(s) at a $72.50 strike. The total cost received by the writing party (or parties) was $44.4K, with a price of $664.0 per contract. There were 6508 open contracts at this strike prior to today, and today 2208 contract(s) were bought and sold. 
• Regarding JANX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JANX#NASDAQ">JANX</a>), we observe a put option trade with bearish sentiment. It expires in 31 day(s) on August 15, 2025. Parties traded 427 contract(s) at a $22.50 strike. The total cost received by the writing party (or parties) was $89.6K, with a price of $210.0 per contract. There were 288 open contracts at this strike prior to today, and today 427 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a call option trade with bearish sentiment. It expires in 10 day(s) on July 25, 2025. Parties traded 50 contract(s) at a $800.00 strike. The total cost received by the writing party (or parties) was $45.5K, with a price of $910.0 per contract. There were 194 open contracts at this strike prior to today, and today 213 contract(s) were bought and sold. 
• Regarding TEVA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>), we observe a call option trade with neutral sentiment. It expires in 66 day(s) on September 19, 2025. Parties traded 130 contract(s) at a $12.00 strike. The total cost received by the writing party (or parties) was $56.2K, with a price of $433.0 per contract. There were 5421 open contracts at this strike prior to today, and today 130 contract(s) were bought and sold. 
• Regarding NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we observe a call option trade with bullish sentiment. It expires in 338 day(s) on June 18, 2026. Parties traded 132 contract(s) at a $70.00 strike. The total cost received by the writing party (or parties) was $128.7K, with a price of $975.0 per contract. There were 1300 open contracts at this strike prior to today, and today 91 contract(s) were bought and sold. 
• For TEM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), we notice a call option trade that happens to be neutral, expiring in 45 day(s) on August 29, 2025. This event was a transfer of 50 contract(s) at a $59.00 strike. The total cost received by the writing party (or parties) was $28.0K, with a price of $560.0 per contract. There were 2 open contracts at this strike prior to today, and today 56 contract(s) were bought and sold. 
• For BBIO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIO#NASDAQ">BBIO</a>), we notice a call option sweep that happens to be neutral, expiring in 31 day(s) on August 15, 2025. This event was a transfer of 35 contract(s) at a $40.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $28.1K, with a price of $805.0 per contract. There were 1699 open contracts at this strike prior to today, and today 42 contract(s) were bought and sold. 
• Regarding TMO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), we observe a put option trade with bullish sentiment. It expires in 549 day(s) on January 15, 2027. Parties traded 25 contract(s) at a $340.00 strike. The total cost received by the writing party (or parties) was $59.2K, with a price of $2370.0 per contract. There were 170 open contracts at this strike prior to today, and today 31 contract(s) were bought and sold. 
• Regarding HCA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>), we observe a put option sweep with bullish sentiment. It expires in 66 day(s) on September 19, 2025. Parties traded 18 contract(s) at a $360.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $25.0K, with a price of $1390.0 per contract. There were 159 open contracts at this strike prior to today, and today 23 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

BBIO

JANX

TEVA

10 Health Care Stocks Whale Activity In Today's Session

Bank of America (BofA) Securities updated the earnings model for Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>). The company&nbsp;will announce second-quarter 2025 <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b46095809/pfizer-invites-public-to-view-and-listen-to-webcast-of-august-5-conference-call-with-analysts" rel="noreferrer noopener">earnings on August 5</a>.
According to data from <a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">Benzinga Pro</a>, analysts estimate adjusted earnings of 57 cents per share on sales of $13.41 billion.
In the second quarter, total revenue decreased by less than 1%, and earnings per share remained unchanged.
Analysts also expect revenue and EPS to stay within 1% of previous forecasts. Revenue will likely decline by a low single-digit percentage in the latter part of the 2020s, they say. This is mainly due to Vyndaqel and Ibrance&#8217;s earlier-than-expected loss of exclusivity.
Read Next: <a href="https://www.benzinga.com/news/legal/25/07/46364944/pfizer-sanofi-find-relief-as-delaware-top-court-rejects-zantac-expert-testimony" target="_blank" rel="noreferrer noopener">Pfizer, Sanofi Find Relief As Delaware Top Court Rejects Zantac Expert Testimony</a>
EPS is also expected to shift up or down by a low single-digit percentage, depending on the year.
BofA maintains the <a target="_blank" href="https://www.benzinga.com/quote/PFE/analyst-ratings" rel="noreferrer noopener">price forecast of $27</a> with a Neutral rating using a 9x P/E multiple on updated 2025 EPS.
Pfizer&#8217;s stock is trading at a price-to-earnings ratio of about 8–9 times its expected 2025 earnings. That&#8217;s lower than the peer average of around 12 times, excluding Eli Lilly &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>).
It also offers a high dividend yield of around 7%, which may help prevent the share price from falling further. However, the long-term outlook is less certain due to upcoming patent expirations and increased competition, which could result in slower-than-average growth.
Pfizer expects its 2025 sales to decline by about $1 billion due to changes under the Inflation Reduction Act (IRA) Part D reform. The company anticipates a $500 million increase in revenue from more patients using its drugs, thanks to lower out-of-pocket costs. However, this is offset by a $1.5 billion loss due to increased costs in the catastrophic phase of Medicare Part D.
Cheaper options (i.e. Eliquis) may benefit from certain reforms more than expensive drugs because the coverage gap is being removed.
In the first quarter of 2025, Pfizer says it already felt a negative impact of around $650 million compared to the same period in 2024, due to higher discount requirements for drugmakers.
Price Action: PFE stock is down 0.64% at $25.49 at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/07/46396808/wolfspeed-wolf-stock-resumes-rally-amid-restructuring-optimism" target="_blank" rel="noreferrer noopener">Wolfspeed (WOLF) Stock Resumes Rally Amid Restructuring Optimism</a></li>
</ul>
Image: Shutterstock

Analyst Color

Earnings

Guidance

Analyst Ratings

Pfizer Faces $1 Billion IRA Reform Hit As Analysts Expect Flat 2025 Outlook

<figure class="wp-block-image aligncenter size-large"><img loading="lazy" decoding="async" width="1024" height="683" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/12214706/Top-Image-1-1024x683.jpg" alt="" class="wp-image-15723" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/12214706/Top-Image-1-1024x683.jpg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/12214706/Top-Image-1-300x200.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/12214706/Top-Image-1-768x512.jpg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/12214706/Top-Image-1.jpg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h2 class="wp-block-heading">Follow-Up: Sana Biotechnology</h2>
6-Month Data, +150 % Rally, and Morgan Stanley's New Overweight Call
In a public <a href="https://www.benzinga.com/general/biotech/25/05/45498697/the-end-of-the-diabetes-industry-this-small-cap-could-upend-the-business-models-of-pharma-giants">post </a>in May, I wrote about Sana Biotechnology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANA#NASDAQ">SANA</a>), a biotech that has developed a potential cure for type 1 diabetes. Here's an update on developments since.
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h3 class="wp-block-heading">1. Quick Recap of the May 19 Thesis</h3>
<ul class="wp-block-list">
<li>Functional-cure potential.&nbsp;Sana's hypo-immune (HIP) edits let donor islet cells make insulin without triggering rejection—no immunosuppression required.</li>
<li>Moat = immune stealth.&nbsp;Removing MHC I/II and adding "don't-eat-me" CD47 is the core advantage.</li>
<li>Industry disruption.&nbsp;If HIP-edited, stem-cell–derived islets (program SC451) scale, legacy diabetes franchises at&nbsp;Novo Nordisk&nbsp;A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>),&nbsp;Eli Lilly and Co.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>),&nbsp;DexCom, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>),&nbsp;Insulet Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>), etc., may be at risk.</li>
</ul>
(See <a href="https://www.benzinga.com/general/biotech/25/05/45498697/the-end-of-the-diabetes-industry-this-small-cap-could-upend-the-business-models-of-pharma-giants">original </a>post for full details.)
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h3 class="wp-block-heading">2. Stock Performance Since the Post</h3>
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="740" height="151" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/12214746/image-13.png" alt="" class="wp-image-15724" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/12214746/image-13.png 740w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/12214746/image-13-300x61.png 300w" sizes="(max-width: 740px) 100vw, 740px" /></figure>
In under eight weeks, SANA has&nbsp;nearly tripled, reflecting a shift from speculative promise to emerging proof-of-concept.
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h3 class="wp-block-heading">3. Six-Month Human Data (June 23)</h3>
<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">"Cells survived, secreted insulin, and responded to meals&nbsp;six months&nbsp;after transplant—without immunosuppression&nbsp;and with&nbsp;no safety issues."&nbsp;<a href="https://www.globenewswire.com/news-release/2025/06/23/3103540/0/en/Sana-Biotechnology-Announces-Positive-Six-Month-Clinical-Results-from-Type-1-Diabetes-Study-of-Islet-Cell-Transplantation-Without-Immunosuppression.html">GlobeNewswire</a>
</blockquote>
Why it matters
<ul class="wp-block-list">
<li>Durability:&nbsp;Continued C-peptide production and meal-stimulated spikes confirm functional beta-cell activity.</li>
<li>Immune evasion:&nbsp;Persistent graft survival validates HIP edits.</li>
<li>Safety:&nbsp;No cell- or procedure-related adverse events.</li>
<li>Path forward:&nbsp;Larger dose-escalation cohorts; IND for stem-cell version (SC451) targeted for 2026.</li>
</ul>
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h3 class="wp-block-heading">4. Morgan Stanley Joins the Bull Camp (July 2)</h3>
<ul class="wp-block-list">
<li>Initiation:&nbsp;Overweight&nbsp;rating,&nbsp;$12 price target&nbsp;(~3× Friday's close).</li>
<li>Rationale: Six- and 12-week human data "de-risk the platform"; broad cell-engineering pipeline offers additional upside. Investing.com</li>
</ul>
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h3 class="wp-block-heading">5. What Could Move the Stock Next</h3>
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<thead>
<tr>
<th>Catalyst</th>
<th>Expected Timing</th>
<th>Significance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Additional patients dosed</td>
<td>2H 2025 – 1H 2026</td>
<td>Reproducibility &amp; dose-response</td>
</tr>
<tr>
<td>Peer-review / ADA + IPITA presentations</td>
<td>2025 conf. season</td>
<td>External validation</td>
</tr>
<tr>
<td>SC451 IND filing</td>
<td>2026</td>
<td>Scalable, off-the-shelf therapy</td>
</tr>
<tr>
<td>Non-dilutive partnerships or grants</td>
<td>Anytime</td>
<td>Cash-burn mitigation</td>
</tr>
</tbody>
</table>
</figure>
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h3 class="wp-block-heading">6. Bottom Line</h3>
<ul class="wp-block-list">
<li>Data + Duration:&nbsp;The six-month update converts "interesting science" into early evidence of&nbsp;durable clinical benefit.</li>
<li>Momentum:&nbsp;A ~150 % rally since May 19 shows the market is starting to price in that shift.</li>
<li>Institutional validation:&nbsp;Morgan Stanley's fresh&nbsp;Overweight&nbsp;adds credibility—and a higher-quality buyer base.</li>
</ul>
If you sized SANA small after the May post, the thesis is tracking; consider letting winners run while watching for pullbacks to add. New capital? Size cautiously—it's still a single-patient read-out—but the upside/skew remains attractive as more data rolls in.
And if you're long legacy diabetes treatment companies, consider hedging them. Although Sana is aiming to cure T1 diabetes, its treatment could potentially impact the market for management of some forms of T2 diabetes as well (e.g., insulin therapy). As a reminder, you can use&nbsp;<a href="https://portfolioarmor.com/">Portfolio Armor's website</a>&nbsp;or&nbsp;<a href="https://apps.apple.com/us/app/portfolio-armor/id394951144">iPhone app</a>&nbsp;to scan for cost-effective hedges.
<figure class="wp-block-image size-large"><a href="https://apps.apple.com/us/app/portfolio-armor/id394951144"><img loading="lazy" decoding="async" width="1024" height="683" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/12214805/PA-JPEG-1-1024x683.jpeg" alt="" class="wp-image-15725" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/12214805/PA-JPEG-1-1024x683.jpeg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/12214805/PA-JPEG-1-300x200.jpeg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/12214805/PA-JPEG-1-768x512.jpeg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/12214805/PA-JPEG-1.jpeg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
And if you want a heads up when we place our next trade, you can subscribe to the Portfolio Armor trading Substack below.&nbsp;
<figure class="wp-block-image size-full"><a href="https://blog.portfolioarmor.com/"><img loading="lazy" decoding="async" width="581" height="372" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/12215355/Widget-1.jpg" alt="" class="wp-image-15726" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/12215355/Widget-1.jpg 581w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/12215355/Widget-1-300x192.jpg 300w" sizes="(max-width: 581px) 100vw, 581px" /></a></figure>

Opinion

DXCM

PODD

SANA

How To Trade This 150% Gainer Chasing A Cure For Type 1 Diabetes

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer said Rocket Lab Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) is a buy, adding that it is &#8220;one of the hottest stocks in the universe.&#8221;
On June 30, the space-tech company notched its fastest launch turnaround ever, completing its 68th Electron mission and signaling a new era of rapid-response rocket deployment.
He also recommended buying Huntington Ingalls Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HII#NYSE">HII</a>).
Supporting his view, TD Cowen analyst Gautam Khanna, on July 10, upgraded Huntington Ingalls <a href="https://www.benzinga.com/quote/HII/analyst-ratings">from Hold to Buy and raised the price target from $250 to $300.</a>
&#8220;This thing is just a coiled spring when we get the new numbers,&#8221; Cramer said when asked about Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>). &#8220;There are many big studies coming down the pipe.&#8221;
Guggenheim analyst Seamus Fernandez, on July 11, maintained Eli Lilly with a Buy and raised the price target from $936 to $942.
When asked about TSS, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSSI#NASDAQ">TSSI</a>), he said, &#8220;That's a pretender. We want to be in CoreWeave if we're going to go there.&#8221;
On the earnings front, TSS, on May 15, reported a year-over-year increase in first-quarter revenue results.
Cramer recommended not buying Conagra Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAG#NYSE">CAG</a>), saying it's a &#8220;very tough situation.&#8221;
The company, on July 10, reported adjusted earnings per share of 56 cents, missing the analyst consensus estimate of 58 cents. Quarterly net sales of $2.78 billion, missed the Street view of $2.83 billion.
Cramer recommended buying NXP Semiconductors N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) on Monday morning.
Lending support to his choice, KeyBanc, on July 8, maintained an Overweight rating and raised the price target from $240 to $275.
Power Solutions International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSIX#NASDAQ">PSIX</a>) is an &#8220;amazing stock, it's not even that expensive,&#8221; Cramer said.
Supporting his view, the company, on May 8, reported a year-over-year increase in first-quarter financial results.
Price Action:
<ul class="wp-block-list">
<li>Huntington Ingalls Industries shares gained 0.03% to settle at $258.18 on Friday.</li>
<li>Rocket Lab shares fell 0.2% to close at $39.03.</li>
<li>TSS shares gained 3.3% to settle at $26.46 on Friday.</li>
<li>Eli Lilly shares gained 0.3% to close at $793.01.</li>
<li>Conagra Brands shares fell 0.5% to settle at $19.40 on Friday.</li>
<li>NXP Semiconductors shares fell 1.8% to close at $228.92.</li>
<li>Power Solutions International shares gained 5.3% to settle at $72.02.</li>
</ul>
Read Next:<a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46364472/top-3-real-estate-stocks-that-may-fall-off-a-cliff-this-month"> </a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46364472/top-3-real-estate-stocks-that-may-fall-off-a-cliff-this-month">Top 3 Real Estate Stocks That May Fall Off A Cliff This Month</a></li>
</ul>
Image: Shutterstock

Long Ideas

SPACE

Media

NXPI

PSIX

RKLB

TSSI

This Is 'One Of The Hottest Stocks In The Universe,' Jim Cramer Says

Deep-pocketed investors have adopted a bearish approach towards Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in LLY usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 89 extraordinary options activities for Eli Lilly. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 41% leaning bullish and 44% bearish. Among these notable options, 25 are puts, totaling $2,353,651, and 64 are calls, amounting to $51,869,753.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $500.0 to $1040.0 for Eli Lilly over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Eli Lilly stands at 1044.75, with a total volume reaching 30,575.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Eli Lilly, situated within the strike price corridor from $500.0 to $1040.0, throughout the last 30 days.
<h3>Eli Lilly Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752264144_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$86.85</td>
<td>$86.25</td>
<td>$86.85</td>
<td>$790.00</td>
<td>$390.8K</td>
<td align="right">505</td>
<td align="right">101</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$86.0</td>
<td>$82.1</td>
<td>$86.0</td>
<td>$860.00</td>
<td>$387.0K</td>
<td align="right">82</td>
<td align="right">135</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$205.8</td>
<td>$203.5</td>
<td>$203.5</td>
<td>$580.00</td>
<td>$366.3K</td>
<td align="right">30</td>
<td align="right">18</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$82.55</td>
<td>$82.45</td>
<td>$82.45</td>
<td>$740.00</td>
<td>$197.7K</td>
<td align="right">133</td>
<td align="right">28</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$53.65</td>
<td>$52.4</td>
<td>$52.4</td>
<td>$790.00</td>
<td>$146.7K</td>
<td align="right">400</td>
<td align="right">69</td>
</tr>
</tbody>
</table>

<h3>About Eli Lilly</h3>
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
In light of the recent options history for Eli Lilly, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Eli Lilly Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 2,047,296, the LLY's price is up by 0.2%, now at $792.27. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 27 days.</li>
</ul>
<h3>What The Experts Say On Eli Lilly</h3>
3 market experts have recently issued ratings for this stock, with a consensus target price of $1004.33.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Overweight rating on Eli Lilly with a target price of $1135. 
&#x2A; An analyst from Guggenheim has decided to maintain their Buy rating on Eli Lilly, which currently sits at a price target of $942. 
&#x2A; Reflecting concerns, an analyst from Guggenheim lowers its rating to Buy with a new price target of $936.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Eli Lilly with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Market Whales and Their Recent Bets on LLY Options

In the latest quarter, 7 analysts provided ratings for Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $952.29, with a high estimate of $1135.00 and a low estimate of $700.00. Observing a downward trend, the current average is 8.26% lower than the prior average price target of $1038.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1752242428_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Eli Lilly. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seamus Fernandez</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$942.00</td>
<td>$936.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1135.00</td>
<td>$1133.00</td>
</tr>
<tr>
<td>Seamus Fernandez</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$936.00</td>
<td>$936.00</td>
</tr>
<tr>
<td>Trung Huynh</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$1050.00</td>
<td>$1100.00</td>
</tr>
<tr>
<td>Rajesh Kumar</td>
<td>HSBC</td>
<td>Lowers</td>
<td>Reduce</td>
<td>$700.00</td>
<td>$1150.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$975.00</td>
<td>-</td>
</tr>
<tr>
<td>Seamus Fernandez</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$928.00</td>
<td>$973.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Eli Lilly. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Eli Lilly compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Eli Lilly's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Eli Lilly's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/LLY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Eli Lilly analyst ratings.</a>
<h2>About Eli Lilly</h2>
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
<h3>Eli Lilly: Delving into Financials</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Over the 3M period, Eli Lilly showcased positive performance, achieving a revenue growth rate of 45.17% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 21.68%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Eli Lilly's ROE excels beyond industry benchmarks, reaching 18.42%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Eli Lilly's ROA stands out, surpassing industry averages. With an impressive ROA of 3.28%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 2.44, caution is advised due to increased financial risk.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Eli Lilly Through 7 Analysts

Guggenheim analyst Seamus Fernandez maintains Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) with a Buy and raises the price target from $936 to $942.

Price Target

Guggenheim Maintains Buy on Eli Lilly, Raises Price Target to $942

While President Donald Trump's proposed 200% tariffs on pharmaceutical imports could potentially squeeze the profit margins, this stock is poised to &#8220;benefit&#8221; from the levies. 
What Happened: Trump announced on Tuesday that the pharma tariffs, part of a Section 232 investigation launched in April, are expected to be detailed by month's end, with a grace period of "about a year, year and a half" before implementation.
Barclays cautioned that a 200% tariff would "inflate production costs, compress profit margins, and risk supply chain disruptions.&#8221; However, the delay offers little relief, <a href="https://www.cnbc.com/2025/07/11/trump-200percent-pharma-tariffs-threaten-to-push-up-drug-prices-hit-margins.html">as</a> CNBC reported, quoting UBS analysts that it's "insufficient time" for firms to relocate manufacturing, typically a four-to-five-year process. 
But despite the potential negative impact on pharma companies, Louis Navellier told <a href="https://www.benzinga.com">Benzinga </a>that Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) is &#8220;expected to benefit from tariffs on pharmaceutical imports, since the company has been boosting its domestic manufacturing.&#8221;
Additionally, Thomas Shipp, head of equity research at LPL Financial, told <a href="https://pro.benzinga.com/dashboard">Benzinga</a> that Lilly's attempt to try &#8220;to avoid PBMs,&#8221; exemplified by its direct-to-consumer model, &#8216;LillyDirect&#8217; in partnership with Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), positions it to bypass traditional pharmacy benefit managers, enhancing its resilience against tariff-related disruptions.
See Also: <a href="https://www.benzinga.com/markets/equities/25/07/46361386/bitcoin-breaches-118k-but-these-btc-mining-firms-are-still-priced-like-its-at-58k-heres-how-these-mining-stocks-could-explode">Bitcoin Breaches $118K, But These BTC Mining Firms Are Still Priced Like It&#8217;s At $58K: Here&#8217;s How These Mining Stocks Could Explode</a>
Why It Matters: Additionally, Lilly's strategic moves, including a $1.3 billion <a href="https://www.benzinga.com/m-a/25/06/45970361/eli-lilly-expands-into-gene-editing-with-verve-therapeutics-acquisition">acquisition of Verve Therapeutics</a>, signal its focus on innovation and U.S.-based growth. 
Ark Research noted that this acquisition validates gene-editing therapies for cardiovascular disease, a market with "trillions of dollars" in potential, as Lilly scales solutions like PCSK9-targeting therapies that reduce LDL-C by up to 69%.
Apart from the effects on the profitability of pharmaceutical companies, according to PhRMA, the tariffs could raise U.S. drug prices by $51 billion annually with just a 25% tariff levy, potentially increasing costs by 12.9%.
Price Action: Eli Lilly stock declined 0.078% in premarket on Friday; it was up 1.62% on a year-to-date basis but down by 15.36% over the last year.
Benzinga Edge Stock Rankings shows that LLY had a weak momentum and value ranking; however, its growth and quality metrics were very strong. The details of all the important indicators are <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-4/#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">available here</a>.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="163" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/11071005/LLY-edge-1024x163.png" alt="" class="wp-image-981662" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/11071005/LLY-edge-1024x163.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/11071005/LLY-edge-300x48.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/11071005/LLY-edge-768x122.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/11071005/LLY-edge.png 1039w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
These are some pharma stocks and ETFs that could be impacted as Trump warned on Tuesday that long-awaited industry-wide tariffs would be announced "very soon".
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Pharma Stocks</td>
<td>YTD Performance</td>
<td>One Year Performance</td>
</tr>
<tr>
<td>Eli Lilly And Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)</td>
<td>1.62%</td>
<td>-15.36%</td>
</tr>
<tr>
<td>AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)</td>
<td>8.67%</td>
<td>14.77%</td>
</tr>
<tr>
<td>Bristol-Myers Squibb Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)</td>
<td>-14.56%</td>
<td>19.07%</td>
</tr>
<tr>
<td>Regeneron Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>)</td>
<td>-21.73%</td>
<td>-48.18%</td>
</tr>
<tr>
<td>Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)</td>
<td>-3.12%</td>
<td>-10.05%</td>
</tr>
<tr>
<td>Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>)</td>
<td>24.66%</td>
<td>63.70%</td>
</tr>
<tr>
<td>Merck &amp; Co Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)</td>
<td>-15.28%</td>
<td>-34.85%</td>
</tr>
<tr>
<td>Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>)</td>
<td>15.85%</td>
<td>-7.60%</td>
</tr>
<tr>
<td>Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)</td>
<td>9.49%</td>
<td>5.34%</td>
</tr>
</tbody>
</table>
</figure>
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Pharma ETFs</td>
<td>YTD Performance</td>
<td>One Year Performance</td>
</tr>
<tr>
<td>VanEck Pharmaceutical ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPH#NASDAQ">PPH</a>)</td>
<td>3.50%</td>
<td>-3.73%</td>
</tr>
<tr>
<td>iShares US Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>)</td>
<td>3.15%</td>
<td>-0.88%</td>
</tr>
<tr>
<td>Invesco Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PJP#NYSE">PJP</a>)</td>
<td>0.68%</td>
<td>-0.49%</td>
</tr>
<tr>
<td>SPDR S&amp;P Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPH#NYSE">XPH</a>)</td>
<td>-0.16%</td>
<td>2.31%</td>
</tr>
<tr>
<td>KraneShares MSCI All China Health Care Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KURE#NYSE">KURE</a>)</td>
<td>25.74%</td>
<td>30.34%</td>
</tr>
<tr>
<td>First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTXH#NASDAQ">FTXH</a>)</td>
<td>-1.00%</td>
<td>-4.29%</td>
</tr>
<tr>
<td>Direxion Daily Pharmaceutical &amp; Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PILL#NYSE">PILL</a>)</td>
<td>-14.12%</td>
<td>-14.74%</td>
</tr>
</tbody>
</table>
</figure>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/07/46336115/as-trump-calls-for-3-percentage-point-rate-cut-too-late-jerome-powell-to-resign-june-fed-minutes-sh">As Trump Calls For 3-Percentage Point Rate Cut, &#8216;Too Late&#8217; Jerome Powell To Resign, June Fed Minutes Show &#8216;Uncertainty&#8217; Reigns Supreme</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image via Shuttertsock

AMGN

AMZN

GILD

REGN

Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies

Morgan Stanley analyst Terence Flynn maintains Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) with a Overweight and raises the price target from $1133 to $1135.

Morgan Stanley Maintains Overweight on Eli Lilly, Raises Price Target to $1135

Deep-pocketed investors have adopted a bullish approach towards Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in LLY usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 40 extraordinary options activities for Eli Lilly. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 55% leaning bullish and 25% bearish. Among these notable options, 6 are puts, totaling $330,318, and 34 are calls, amounting to $5,397,011.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $370.0 to $990.0 for Eli Lilly over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Eli Lilly options trades today is 321.08 with a total volume of 4,088.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Eli Lilly's big money trades within a strike price range of $370.0 to $990.0 over the last 30 days.
<h3>Eli Lilly Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752163269_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$169.0</td>
<td>$169.0</td>
<td>$169.0</td>
<td>$750.00</td>
<td>$1.6M</td>
<td align="right">617</td>
<td align="right">98</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$168.85</td>
<td>$167.0</td>
<td>$168.85</td>
<td>$750.00</td>
<td>$472.7K</td>
<td align="right">617</td>
<td align="right">164</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$168.85</td>
<td>$167.0</td>
<td>$168.85</td>
<td>$750.00</td>
<td>$320.8K</td>
<td align="right">617</td>
<td align="right">183</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/17/25</td>
<td>$49.5</td>
<td>$49.15</td>
<td>$49.5</td>
<td>$830.00</td>
<td>$297.0K</td>
<td align="right">182</td>
<td align="right">102</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$169.0</td>
<td>$168.85</td>
<td>$169.0</td>
<td>$750.00</td>
<td>$287.3K</td>
<td align="right">617</td>
<td align="right">126</td>
</tr>
</tbody>
</table>

<h3>About Eli Lilly</h3>
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
<h3>Where Is Eli Lilly Standing Right Now?</h3>
<ul>
<li>With a volume of 1,089,317, the price of LLY is up 1.15% at $795.98. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 28 days.</li>
</ul>
<h3>Professional Analyst Ratings for Eli Lilly</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $936.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Guggenheim has revised its rating downward to Buy, adjusting the price target to $936. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Eli Lilly, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

This Is What Whales Are Betting On Eli Lilly

Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) is set to release its second-quarter earnings on August 7. According to&nbsp;<a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">Benzinga Pro</a> data,&nbsp;analysts are anticipating adjusted earnings of $5.56 per share and sales of $14.4 billion.
Expectations are slightly higher for the quarter, primarily driven by the strong performance of its obesity drug, Zepbound. The pharmaceutical giant, a dominant player in the incretin/GLP-1 drug market for obesity and diabetes, continues to draw investor attention with its robust pipeline and long-term growth prospects.
<h2 class="wp-block-heading">Analyst Adjustments and Forecasts</h2>
Ahead of the earnings release, Bank of America Securities (BofA) has made minor adjustments to its earnings model for Eli Lilly.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/fda/25/07/46319441/fda-approves-new-dosing-schedule-for-eli-lillys-kisunla-in-alzheimers-treatment" rel="noreferrer noopener">FDA Approves New Dosing Schedule For Eli Lilly&#8217;s Kisunla In Alzheimer&#8217;s Treatment</a>
BofA analyst Tim Anderson specifically noted a slight, low single-digit percentage increase in <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">second-quarter revenue</a> and EPS forecasts, primarily driven by stronger anticipated sales of Zepbound.
Looking further out, the analyst updated full-year projections, expecting total revenue to rise by 1% and 0.4% in 2025, with EPS growing by 1.9% in 2025 but experiencing a slight dip of 0.7% in 2026.
Beyond 2026, revenue and EPS projections largely remain consistent. Importantly, long-term forecasts for Lilly&#8217;s key products, Mounjaro, Zepbound, orforglipron, and retatrutide, have not seen significant revisions.
<h2 class="wp-block-heading">BofA Maintains Buy Rating</h2>
BofA maintains a Buy rating on Eli Lilly, with a <a target="_blank" href="https://www.benzinga.com/quote/LLY/analyst-ratings" rel="noreferrer noopener">price forecast of $1,000</a>. This reflects the firm&#8217;s view of Lilly&#8217;s exceptional and sustainable growth potential compared to its peers, at what is considered a reasonable valuation.
The core focus of the company remains its incretin/GLP-1 drugs for obesity and diabetes, a market where Lilly is expected to maintain a leading position in the foreseeable future alongside one other top company.
<h2 class="wp-block-heading">Key Focus Areas for the Earnings Call</h2>
The earnings call will focus on several key areas. Broader concerns around U.S. drug pricing changes, including the &#8216;most favored nation&#8217; proposal and possible pharma-related tariffs under Section 232, are expected to be discussed.
Important upcoming clinical trial results, such as tirzepatide&#8217;s SURPASS-CVOT, orforglipron&#8217;s ATTAIN-1, and Novo Nordisk A/S&#8217; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) REDEFINE-4, will also be a point of interest.
Performance updates on major products, especially Mounjaro and Zepbound, will be closely watched. Additionally, early launch progress for new drugs like Kisunla for Alzheimer&#8217;s and Ebglyss for eczema will be highlighted.
Price Action: LLY stock is trading higher by 0.82% to $784.07 at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/07/46324159/why-china-automotive-systems-stock-is-gaining-on-wednesday" target="_blank" rel="noreferrer noopener">Why China Automotive Systems Stock Is Gaining On Wednesday</a></li>
</ul>
Photo via Shutterstock

Reiteration

Topics

Zepbound Powers Eli Lilly's Upbeat Q2 Outlook

The U.S. Food and Drug Administration (FDA) has approved a label update with a new recommended titration dosing schedule for Eli Lilly and Co.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Kisunla (donanemab-azbt) once-monthly amyloid-targeting therapy for adults with early symptomatic Alzheimer&#8217;s disease (AD). The FDA approved the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39620867/eli-lillys-alzheimers-therapys-broad-label-reflects-regulatory-confidence-in-anti-a" target="_blank" rel="noreferrer noopener">drug in July 2024</a>.
In the <a href="https://www.benzinga.com/general/biotech/24/10/41608511/eli-lilly-says-new-data-can-potentially-provide-path-to-improved-donanemab-profile-by-lower-risk-" target="_blank" rel="noreferrer noopener">TRAILBLAZER-ALZ 6 study</a>, the modified titration schedule significantly reduced the incidence of amyloid-related imaging abnormalities with edema/effusion (ARIA-E) compared to the original dosing schedule at 24 and 52 weeks, while still achieving similar levels of amyloid plaque removal <a href="https://www.benzinga.com/pressreleases/25/07/n46314838/fda-approves-updated-label-for-lillys-kisunla-donanemab-azbt-with-new-dosing-in-early-symptomatic-" target="_blank" rel="noreferrer noopener">and P-tau217 reduction</a>.
The new recommended dosing regimen involves a more gradual titration.
ARIA-E is a side effect of amyloid plaque-targeting therapies, including Kisunla. ARIA-E is usually asymptomatic, although serious and fatal events can occur.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44175948/alzheimers-drugs-from-eli-lilly-and-biogen-still-deemed-too-costly-for-nhs-funding" rel="noreferrer noopener">Alzheimer&#8217;s Drugs From Eli Lilly And Biogen Still Deemed Too Costly For NHS Funding</a>
The new dosing recommendation differs from the original dosing by shifting a single vial from the first dose to the third dose, delivering the same amount of Kisunla by week 24.
This resulted in lower rates of ARIA-E without compromising Kisunla&#8217;s ability to reduce amyloid plaque or its once-monthly dosing, with the potential for a limited-duration treatment based on amyloid plaque removal to minimal levels.
Key findings from the TRAILBLAZER-ALZ 6 study, which supports this label update, included:
<ul class="wp-block-list">
<li>The results showed that the incidence of ARIA-E was 14% in patients receiving the modified titration regimen compared with 24% for those receiving the original dosing regimen, representing a 41% lower relative risk.</li>
<li>At week 52, the incidence of ARIA-E was 16% in patients receiving the modified titration compared with 25% for those receiving the original dosing regimen, a 35% lower relative risk.</li>
<li>Including asymptomatic radiographic events at week 52, ARIA, ARIA-E, and ARIA-H were observed in 29%, 16%, and 25% of patients receiving the modified titration dosing.</li>
<li>ARIA-E and ARIA-H are different types of amyloid-related imaging abnormalities (ARIA). ARIA with edema is characterized as ARIA-E, and ARIA with hemosiderin deposition is characterized as ARIA-H.</li>
</ul>
Patients on the modified titration experienced a reduction of amyloid plaque and P-tau217 comparable to patients receiving the original dosing regimen.
At 24 weeks, amyloid plaque levels in patients on the modified titration of donanemab in TRAILBLAZER-ALZ 6 were reduced on average by 67% from baseline compared to 69% for patients on the original dosing regimen.
No new adverse reactions were identified in the study, although higher rates of hypersensitivity and infusion-related reactions were observed.
In March, the European Medicines Agency&#8217;s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued an opinion that does not recommend Eli Lilly&#8217;s donanemab be granted marketing authorization in early symptomatic Alzheimer&#8217;s disease. Lilly will seek <a href="https://www.benzinga.com/25/03/44544761/european-drug-regulator-gives-thumbs-down-to-eli-lillys-alzheimers-drug-analyst-says-it-is-incremental-win-for-biogen" target="_blank" rel="noreferrer noopener">re-examination by CHMP</a>.
Price Action: LLY stock is up 0.30% at $780 during the premarket session at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/m-a/25/07/46317822/merck-strikes-10-billion-deal-for-verona-secures-first-in-class-copd-drug" target="_blank" rel="noreferrer noopener">Merck Strikes $10-Billion Deal For Verona, Secures First-In-Class COPD Drug</a></li>
</ul>
Photo: Shutterstock

FDA Approves New Dosing Schedule For Eli Lilly's Kisunla In Alzheimer's Treatment

The FDA Approves Eli Lilly's Label Update With A New Recommended Titration Dosing Schedule For Kisunla (Donanemab-azbt), Once-monthly Amyloid-targeting Therapy For Adults With Early Symptomatic Alzheimer's Disease

Press Releases

Lilly presents first clinical data for its investigational, next-generation FRα targeting ADC in platinum-resistant ovarian cancer at the 2025 ASCO Annual Meeting

Lilly to participate in Goldman Sachs 46th Annual Global Health Care Conference

Lilly to offer all approved doses of Zepbound (tirzepatide) single-dose vials through LillyDirect Self Pay Pharmacy Solutions

Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk

VERVE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verve Therapeutics, Inc. - VERV

Lilly's oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The New England Journal of Medicine

Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials

Dividends

Lilly declares third-quarter 2025 dividend

Small Cap

New AI Rollouts Signal Shift From Hype to Healthcare Reality

FDA approves updated label for Lilly's Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer's disease

AVAI

PLTR

VERV

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Ligand Pharmaceuticals Incorporated - Common Stock

Ligand Pharmaceuticals

Merck & Co

Novartis

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Comments

Eli Lilly

Unusual Options Activity for

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Date	Put/Call	Strike Price	Exp Date	DTE	Trade Vol	Day Vol	Vol / OI	OI	Trade Type	Sentiment
11:00 AMJul 21, 2025	PUT	$600.00	Jun 17, 2027	694	110	100	88	125	TRADE	NEUTRAL
09:30 AMJul 21, 2025	CALL	$500.00	Mar 20, 2026	240	0	200	0	332	SWEEP	BULLISH
02:14 PMJul 18, 2025	CALL	$500.00	Mar 20, 2026	240	697	22	17425	4	SWEEP	BULLISH
01:42 PMJul 18, 2025	CALL	$500.00	Mar 20, 2026	240	600	37	15000	4	SWEEP	BULLISH
01:39 PMJul 18, 2025	CALL	$500.00	Mar 20, 2026	240	600	26	15000	4	SWEEP	BEARISH
01:33 PMJul 18, 2025	CALL	$500.00	Mar 20, 2026	240	555	30	13875	4	SWEEP	BEARISH
01:33 PMJul 18, 2025	CALL	$500.00	Mar 20, 2026	240	503	22	12575	4	SWEEP	NEUTRAL
09:34 AMJul 18, 2025	CALL	$500.00	Mar 20, 2026	240	100	100	2500	4	SWEEP	BEARISH
09:30 AMJul 18, 2025	CALL	$400.00	Mar 20, 2026	240	0	93	0	3	TRADE	BEARISH
01:37 PMJul 17, 2025	CALL	$600.00	Sep 19, 2025	58	201	100	353	57	SWEEP	BEARISH
10:04 AMJul 16, 2025	PUT	$620.00	Jun 18, 2026	330	200	200	43	461	TRADE	NEUTRAL
09:54 AMJul 16, 2025	CALL	$780.00	Aug 01, 2025	9	440	356	55	801	TRADE	BULLISH
12:08 PMJul 15, 2025	CALL	$780.00	Aug 01, 2025	9	287	270	101	283	TRADE	BULLISH